Evidence map›Paper›PMID 24866501›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2014

A pharmacological paradox: may a neutral antagonist shift an agonist concentration-response curve to the left?

Thomas J Feuerstein

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Thomas J FeuersteinFreiburg Institute for Advanced Studies (FRIAS), University of Freiburg, 79104, Freiburg, Germany, thomas.feuerstein@uniklinik-freiburg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is generally accepted that the presence of a competitive antagonist shifts an agonist concentration-response curve to the right. However, this may not always be the case: The concentration-response curve of an inverse receptor agonist may be shifted to the left by a neutral antagonist; a condition, which can be hypothetically explained by the assumption of both negative cooperativity of dimeric receptors plus a receptor reserve.

Indexed as

AnimalsCannabinoid Receptor AntagonistsDronabinolHippocampusMaleNorepinephrinePiperidinesPyransPyrazolesReceptor, Cannabinoid, CB1Rimonabant(6aR,10aR)-3-(1-methansulfonylamino-4-hexyn-6-yl)6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyranCannabinoid Receptor AntagonistsDronabinolNorepinephrinePiperidinesPyransPyrazolesReceptor, Cannabinoid, CB1Rimonabant

Identifiers

PMID24866501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.